Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Share News (APH)

Share Price Information for Alliance Pharma (APH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.80
Bid: 38.85
Ask: 39.15
Change: 0.00 (0.00%)
Spread: 0.30 (0.772%)
Open: 39.00
High: 39.00
Low: 38.80
Prev. Close: 38.80
APH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: HSBC announces redemption of US dollar securities

Thu, 15th Apr 2021 19:37

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

HSBC Holdings PLC - London-based bank - Announces the redemption of its USD2.00 billion 6.875% perpetual subordinated contingent convertible securities. The redemption price will be USD1,000 per USD1,000 of the securities together with any accrued but unpaid interest.

----------

RHI Magnesita NV - Vienna, Austria-headquartered supplier of refractory products - Notes appointment of Non-Executive Director Janet Ashdown as an independent non-executive director of Stolt-Nielsen Ltd, listed on the Oslo Bors.

----------

Blue Star Capital PLC - investment company with a focus on esports, payments, technology and its applications within media and gaming - Says investee Dynasty eSports Pte Ltd achieved its first monthly profit on an operating basis in January. Says Dynasty expects to shortly conclude a round of fundraising in which it is targeting to raise approximately USD5 million. Blue Star retains anti-dilution rights and is considering exercising these rights to participate in Dynasty's fundraising round. Blue Star currently holds approximately 13% of Dynasty.

----------

Alliance Pharma PLC - pharmaceutical company based in Wiltshire - Says Non-Executive Director Nigel Clifford to step down on April 30 after serving for six years.

----------

Futura Medical PLC - Surrey-based pharmaceutical company - Receives conversion notice from HT Riverwood Multi-Growth Fund, managed by Atlantis Investment Management Ltd, for GBP1.5 million loan notes. Says following this there will be no further amounts outstanding to Riverwood. Says following the conversion, Futura will issue 7.5 million shares at a conversion price of 20 pence per share.

----------

CEPS PLC - Bath, England-based investment company focussed on the industrial sector - Says subsidiary Hickton Group Ltd enters a four-year GBP500,000 Coronavirus Business Interruption Loan with Santander UK PLC. Proceeds will be used for general corporate purposes. Says the loan is repayable in 11 consecutive equal quarterly payments starting approximately 12 months after drawdown.

----------

Tavistock Investments PLC - Berkshire-based investment manager - Says holders of 42% of its shares are against possible Team PLC offer. On Wednesday, Tavistock received letters of intent from holders of 25% of shares saying they will reject the possible all-share offer by Team. In addition, Tavistock board members, who own a 16% stake, would not accept an offer at that level from Team as it significantly undervalues the business. On March 23, Jersey-based investment manager Team announced a possible all-share offer for Tavistock worth GBP15.2 million, or 2.5 pence per share. Tavistock's market capitalisation is GBP15.8 million.

----------

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Withdraws application for maintenance of Europe Efmody orphan designation. Says this follows feedback from the Committee for Orphan Medicinal Products, an advisory committee to the European Medicines Agency. "Diurnal has decided that continuing pursuit of an Orphan Designation for the drug would be likely to cause a significant delay in its European commercial launch. First commercial launch is currently anticipated to be in Q3 2021," says Diurnal.

----------

Emmerson PLC - Khemisset potash project in northern Morocco - Completes phased development plan for Khemisset potash project. Expects "significantly reduced up-front capex" of USD254.6 million. Expects earnings before interest, tax, depreciation and amortisation in first full year of phase four production of USD491.4 million.

----------

CATCo Reinsurance Opportunities Fund Ltd - investor focused on offering returns from investments linked to catastrophe reinsurance risks - Advised of further side pocket investment release amounting to USD19.2 million. Says it is expected to be paid to the company in May, following which the company intends to use it to carry out a seventh compulsory redemption of its shares.

----------

Caerus Mineral Resources PLC - exploration & resource development company focused on minerals in Europe to supply global clean energy drive - Says drilling in Cyprus has begun ahead of schedule. Says Mines Department of Cyprus has accepted its applications for the Kapedes and Vrechia extension licences. Says formal granting of licences expected to take several months but will commence reconnaissance geological mapping and sampling in the interim.

----------

Valeura Energy Inc - Canada-based company engaged in the exploration, development and production of petroleum and natural gas in Turkey - Agrees with TBNG Ltd to amend long stop date for completion of the sale of its shallow conventional gas business for USD15.5 million. Valeura will be entitled to royalty payments over a five-year period, with a minimum royalty payment of USD1.0 million, and maximum of USD2.5 million.

----------

Chesterfield Resources PLC - copper explorer focused on Cyprus - Announces that it has commenced its 2021 mineral exploration campaign in Cyprus. The company is exploring for further copper, gold, zinc and silver, after its successful diamond drill programme of late 2020. Says 15 percussion drill holes are planned during April and May.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
12 Dec 2019 16:11

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
27 Nov 2019 15:00

Alliance Pharma handing back 'Xonvea' rights to Duchesnay

(Sharecast News) - Alliance Pharma has reached agreement with Duchesnay of Canada to return the UK and EU licensing rights to 'Xonvea', a prescription medicine for the treatment of nausea and vomiting of pregnancy where conservative management has failed, it announced on Wednesday.

Read more
27 Nov 2019 12:33

Alliance Pharma Exits Xonvea Licensing Deal Amid Slow Sales Uptake

Alliance Pharma Exits Xonvea Licensing Deal Amid Slow Sales Uptake

Read more
17 Sep 2019 16:12

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 18 September KingfisherHalf Year ResultsAccesso TechnologyHalf Year Year Year

Read more
10 Jul 2019 16:12

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 11 July Kenmare ResourcesHalf Year ProductionMcBrideTrading GroupFull

Read more
1 Jul 2019 15:35

Alliance Pharma Founder & Former Chief Executive John Dawson Departs

(Alliance News) - Alliance Pharma PLC said on Monday founder & former chief executive John Dawson decided to step down from the board.Dawson, who was a non-executive director at the on

Read more
16 May 2019 17:55

UK Shareholder Meetings Calendar - Next 7 Days

Friday 17 MayRestaurant GroupBank of Georgia GroupCentaur MediaCairn Continental 20

Read more
10 Apr 2019 16:05

Alliance Pharma's 'Xonvea' gets approval in Ireland

(Sharecast News) - Alliance Pharma announced on Wednesday that 'Xonvea' has gained marketing approval in the Republic of Ireland from the country's medicines regulator, the Health Products Regulatory Authority, for the treatment of nausea and vomiting of pregnancy where conservative management has failed.

Read more
10 Apr 2019 12:27

Alliance Pharma Gets Approval For Anti-Nausea Drug Xonvea In Ireland

LONDON (Alliance News) - Alliance Pharma PLC on Wednesday said its Xonvea drug has been approved in Ireland to treat nausea and vomiting of pregnancy.The Irish marketing approval is first

Read more
26 Mar 2019 11:33

Alliance Pharma Raises Annual Dividend Amid Strong Revenue Growth

LONDON (Alliance News) - Alliance Pharma on Tuesday raised its dividend for 2018 amid a strong revenue performance, though profit fell due to impairments.The pharmaceutical retailer said to

Read more
19 Mar 2019 16:07

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 20 March KingfisherFull Year ResultsCentaur MediaFull Year GroupHalf

Read more
21 Jan 2019 12:42

Alliance Pharma's revenues climb as 'star' products shine

(Sharecast News) - Alliance Pharma on Monday reported a jump in revenue after a strong performance from its 'star' products and newly acquired Nizoral brand.

Read more
14 Jan 2019 15:59

UK Earnings, Trading Statements Calendar - Next 7 Days

Tuesday 15 January Boohoo GroupTrading Statement Gym GroupTrading Workshop Year Year

Read more
2 Oct 2018 09:56

Alliance Pharma launches Xonvea in the UK

(Sharecast News) - Alliance Pharma launched its prescription product for the treatment of nausea and vomiting of pregnancy across the UK on Tuesday.

Read more
1 Oct 2018 13:02

Strategic Equity Capital Underperforms Against Benchmark In Year

LONDON (Alliance News) - Strategic Equity Capital PLC said on Monday it underperformed against its benchmark for its recently ended financial year, due to an undervalued portfolio.The said

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.